What is Augmenta Bioworks?
Augmenta Bioworks operates at the intersection of immunology and computational biology. The company utilizes its proprietary DeepGrid platform to decode the complexities of natural human immunity, providing a high-resolution view of immune receptors. This technological edge allows the firm to partner with global pharmaceutical entities and research institutions to accelerate the development of therapeutic antibodies, cell therapies, and next-generation vaccines. By identifying specific immune responses, Augmenta Bioworks is effectively bridging the gap between biological discovery and clinical application, positioning itself as a critical infrastructure provider in the drug development pipeline.
How much funding has Augmenta Bioworks raised?
Augmenta Bioworks has raised a total of $338K across 2 funding rounds:
Debt
$150K
Debt
$188K
Debt (2020): $150K with participation from PPP
Debt (2021): $188K led by PPP
Key Investors in Augmenta Bioworks
PPP
Public-Private Partnership
What's next for Augmenta Bioworks?
With the recent influx of capital, Augmenta Bioworks is poised to transition into a more aggressive phase of commercialization and research expansion. The strategic focus will likely center on enhancing the throughput of the DeepGrid platform and deepening collaborative efforts with major biotech stakeholders. As the company matures, the emphasis will shift toward validating its therapeutic candidates in clinical settings, thereby transforming its immune-mapping insights into tangible patient outcomes. This late-stage funding environment provides the necessary runway to sustain long-term R&D cycles while maintaining a competitive advantage in the rapidly evolving landscape of precision medicine.
See full Augmenta Bioworks company page
